These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9526578)

  • 1. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
    De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro MG; Attili A; Maltoni C; Del Turco MR; Decensi A; D'Aiuto G; Veronesi U
    Tumori; 1997; 83(6):884-94. PubMed ID: 9526578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR).
    Cassano E; Coopmans de Yoldi G; Ferranti C; Costa A; Mascotti G; De Palo G; Veronesi U
    Eur J Cancer; 1993; 29A(15):2161-3. PubMed ID: 8297658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
    Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
    J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability.
    Mariani L; Formelli F; De Palo G; Manzari A; Camerini T; Campa T; Di Mauro MG; Crippa A; Delle Grottaglie M; Del Vecchio M; Marubini E; Costa A; Veronesi U
    Tumori; 1996; 82(5):444-9. PubMed ID: 9063520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.
    Costa A; De Palo G; Decensi A; Formelli F; Chiesa F; Nava M; Camerini T; Marubini E; Veronesi U
    Ann N Y Acad Sci; 1995 Sep; 768():148-62. PubMed ID: 8526344
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
    Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U
    J Clin Oncol; 2001 Mar; 19(6):1664-70. PubMed ID: 11250995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
    Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
    Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
    Cazzaniga M; Varricchio C; Montefrancesco C; Feroce I; Guerrieri-Gonzaga A
    J Biomed Biotechnol; 2012; 2012():172897. PubMed ID: 22500077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
    Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
    J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
    J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [-Results of ongoing breast cancer prevention studies-].
    Jungi WF
    Arch Gynecol Obstet; 1995; 256 Suppl():S116-21. PubMed ID: 8619644
    [No Abstract]   [Full Text] [Related]  

  • 15. Accrual issues for chemoprevention trials: the example of the 4-HPR study for the prevention of contralateral breast cancer.
    Camerini T; De Palo G; Mariani L; Marubini E; Costa A; Veronesi U
    Tumori; 1999; 85(4):299-303. PubMed ID: 10587038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenretinide: a prototype cancer prevention drug.
    Malone W; Perloff M; Crowell J; Sigman C; Higley H
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1829-42. PubMed ID: 14585058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia.
    Chiesa F; Tradati N; Marazza M; Rossi N; Boracchi P; Mariani L; Formelli F; Giardini R; Costa A; De Palo G
    J Cell Biochem Suppl; 1993; 17F():255-61. PubMed ID: 8412202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.
    Veronesi U; Mariani L; Decensi A; Formelli F; Camerini T; Miceli R; Di Mauro MG; Costa A; Marubini E; Sporn MB; De Palo G
    Ann Oncol; 2006 Jul; 17(7):1065-71. PubMed ID: 16675486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of breast cancer with fenretinide.
    Veronesi U; De Palo G; Costa A; Formelli F; Decensi A
    IARC Sci Publ; 1996; (136):87-94. PubMed ID: 8791119
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results.
    Chiesa F; Tradati N; Marazza M; Rossi N; Boracchi P; Mariani L; Clerici M; Formelli F; Barzan L; Carrassi A
    Eur J Cancer B Oral Oncol; 1992 Oct; 28B(2):97-102. PubMed ID: 1306735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.